BioCryst (BCRX) AI Stock Analysis

• Market Cap: $1.43B
• Dividend Yield: N/A
• Average Volume (3M): 3.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: 45.38%
• EPS Growth: 92.85%
• Country: US
• Employees: 580
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 210,739,060
• 10 Day Avg. Volume: 4,305,156
• 30 Day Avg. Volume: 3,844,100
• PEG Ratio: 0.28
• Price to Book (P/B): -3.27
• Price to Sales (P/S): 3.45
• P/FCF Ratio: -29.25
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: 3.57
• Enterprise Value/Gross Profit: 3.66
• Enterprise Value/Ebitda: 25.50
• 1Y Price Target: $19.80
• Price Target Upside: 192.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): 0.32
• Revenue Forecast (FY): $660.37M

• Rating: 52 Neutral
• Price Target: $7.50 ▲(10.62% Upside)

The score is held back primarily by weak financial fundamentals (negative equity, leverage risk, and negative operating/free cash flow). Offsetting this, the latest earnings call was notably constructive with raised ORLADEYO guidance and improved non-GAAP profitability, while technicals are moderately positive and valuation remains unattractive due to a negative P/E and no dividend support.

Positive Factors

FDA Approval for Pediatric HAE Drug

The FDA approval for a pediatric formulation of ORLADEYO expands BioCryst's market reach and strengthens its competitive position in the HAE treatment space, potentially driving long-term revenue growth.

Strategic Acquisition of Astria Therapeutics

Acquiring Astria Therapeutics is expected to bolster BioCryst's product pipeline and market position, providing strategic growth opportunities and enhancing its competitive edge in rare disease treatments.

Revenue Growth and Guidance

Strong revenue growth and increased guidance for ORLADEYO highlight BioCryst's successful market penetration and product adoption, supporting a positive long-term financial outlook.

Negative Factors

High Leverage and Negative Equity

High leverage and negative equity indicate financial instability, posing risks to BioCryst's long-term solvency and limiting its ability to invest in growth opportunities.

Cash Flow Challenges

Persistent cash flow challenges could hinder BioCryst's ability to fund operations and strategic initiatives, impacting its financial flexibility and long-term sustainability.

Profitability Issues

Ongoing profitability issues, as indicated by negative net margins, suggest difficulties in achieving sustainable earnings, potentially affecting BioCryst's long-term financial health.

BioCryst Business Overview & Revenue Model

Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

How the Company Makes Money

BioCryst generates revenue primarily through the sale of its approved products, particularly ORLADEYO, which is marketed directly to patients and healthcare providers. In addition to product sales, the company may also earn revenue from strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships can involve upfront payments, milestone payments based on development progress, and royalties on future sales of products developed from these collaborations. The company’s focus on rare diseases often allows for premium pricing of its therapies, further enhancing its revenue potential.

BioCryst Financial Statement Overview

Summary

BioCryst is experiencing revenue growth but faces significant challenges in profitability and financial stability. The high leverage and negative equity position pose risks, while cash flow issues further complicate the financial outlook.

Income Statement

BioCryst has shown a positive revenue growth trend with a 7.59% increase in the TTM period. However, the company is still struggling with profitability, as indicated by a negative net profit margin of -1.46% and a low EBIT margin of 8.47%. The gross profit margin remains strong at 97.39%, suggesting efficient cost management, but the overall profitability metrics indicate challenges in achieving net income.

Balance Sheet

The balance sheet reflects a high level of leverage with a negative debt-to-equity ratio of -1.75, indicating significant financial risk. The company has negative stockholders' equity, which is concerning. Return on equity is positive at 1.93%, but this is due to the negative equity base rather than strong performance. The equity ratio is not favorable, indicating potential solvency issues.

Cash Flow

BioCryst's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow growth rate is negative at -137.36% for the TTM period, highlighting cash flow difficulties. However, the free cash flow to net income ratio is positive at 1.13, suggesting that cash flow generation relative to net income is somewhat stable, albeit from a negative base.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	599.82M	450.71M	331.41M	270.83M	157.17M	17.81M
Gross Profit	583.80M	438.23M	326.75M	264.23M	149.91M	16.14M
EBITDA	83.87M	12.81M	-116.33M	-143.85M	-121.74M	-167.56M
Net Income	-8.78M	-88.88M	-226.54M	-247.12M	-184.06M	-182.81M
Balance Sheet
Total Assets	446.42M	490.42M	516.96M	550.00M	588.15M	334.71M
Cash, Cash Equivalents and Short-Term Investments	212.87M	321.06M	388.99M	424.31M	507.60M	300.37M
Total Debt	683.11M	841.42M	825.15M	741.45M	593.24M	279.50M
Total Liabilities	834.31M	966.35M	972.49M	844.60M	695.14M	353.98M
Stockholders Equity	-387.89M	-475.93M	-455.53M	-294.60M	-106.99M	-19.26M
Cash Flow
Free Cash Flow	47.34M	-53.14M	-97.31M	-163.20M	-144.54M	-137.73M
Operating Cash Flow	49.68M	-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
Investing Cash Flow	87.59M	52.59M	-131.50M	-128.24M	15.80M	-6.86M
Financing Cash Flow	-135.48M	-5.76M	32.48M	88.03M	359.67M	302.70M

BioCryst Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Negative. The current price of 6.78 is below the 20-day moving average (MA) of 7.45, below the 50-day MA of 7.31, and below the 200-day MA of 8.23, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 36.70 is Neutral, neither overbought nor oversold. The STOCH value of 6.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCRX.

BioCryst Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	79 Outperform	$2.01B	27.14	20.65%	―	20.62%	―
CDTX	68 Neutral	$6.96B	-18.79	-68.70%	―	-100.00%	53.89%
VCEL	65 Neutral	$1.89B	155.02	4.52%	―	14.05%	241.86%
CLDX	53 Neutral	$1.75B	―	-32.44%	―	-73.94%	-31.70%
BCRX	52 Neutral	$1.43B	-143.34	―	―	45.38%	92.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRPT	51 Neutral	$2.39B	-7.88	-21.37%	―	47.15%	-311.26%

BioCryst Corporate Events

BioCryst Updates ORLADEYO Revenue Outlook and Guidance

On January 12, 2026, BioCryst Pharmaceuticals reported that preliminary, unaudited net revenue from its HAE drug ORLADEYO reached $151 million in the fourth quarter of 2025, up 22% year-on-year (36% on a comparable basis excluding prior European sales), and $601 million for full-year 2025, a 37% annual increase that surpassed its previous guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue following the sale of its European business, full-year 2025 ORLADEYO revenue was $563 million, representing 43% year-on-year growth on a comparable basis, while cash, cash equivalents, restricted cash and investments stood at $338 million as of December 31, 2025; looking ahead, the company guided 2026 global ORLADEYO net revenue to $625 million–$645 million and total revenue to $635 million–$660 million, and outlined a 2026 non-GAAP operating expense range of $380 million–$390 million, rising to $450 million–$470 million including the anticipated Astria Therapeutics acquisition costs, underscoring its expectation of continued non-GAAP profitability and an expanded HAE franchise as it integrates Astria’s navenibart program and pursues further growth in rare-disease therapeutics.

The most recent analyst rating on (BCRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Raises Price of Key ORLADEYO Treatment

Effective January 9, 2026, BioCryst Pharmaceuticals raised the U.S. wholesale acquisition cost of its hereditary angioedema treatment ORLADEYO (berotralstat) from $44,484.33 to $48,487.92 per 28-day pack, covering both the 150 mg and 110 mg capsule strengths, marking a notable price increase for one of the company’s key rare-disease products and with potential implications for payers and patient access.

The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Gains FDA Approval for Pediatric HAE Drug

On December 12, 2025, BioCryst Pharmaceuticals announced the FDA approval of its new drug application for an oral pellet formulation of ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to less than 12 years. This approval marks a significant milestone as it introduces the first and only oral prophylactic treatment for this age group, offering a more convenient administration method compared to previous intravenous or subcutaneous options. The approval was supported by positive interim data from the APeX-P clinical trial, which demonstrated early and sustained reductions in monthly attack rates. The new formulation aims to alleviate the treatment burden for young patients and their caregivers, potentially transforming the management of HAE in children.

The most recent analyst rating on (BCRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Announces Board Chair Transition Plan

On December 9, 2025, Nancy J. Hutson, Ph.D. announced her intention to retire from BioCryst Pharmaceuticals’ Board of Directors, effective by the earlier of the company’s 2026 annual meeting or the closing of its proposed acquisition of Astria Therapeutics. Dr. Hutson, who has served as Chair of the Board and various committees, cited no disagreements with the company. In response, the Board elected Vincent J. Milano as the next Chair, effective upon her retirement.

The most recent analyst rating on (BCRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Announces Early Termination for Astria Merger

On December 3, 2025, BioCryst Pharmaceuticals announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics. This development satisfies one of the conditions for the merger, which is expected to close in the first quarter of 2026, pending other customary closing conditions. The merger is anticipated to enhance BioCryst’s market position, although it carries risks such as potential integration challenges and financial implications.

The most recent analyst rating on (BCRX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Reports Q3 2025 Financial Growth and Strategy

In the third quarter of 2025, BioCryst Pharmaceuticals reported significant financial growth, with ORLADEYO net revenue reaching $159.1 million, a 37% increase year-over-year. The company completed the sale of its European ORLADEYO business, using proceeds to retire Pharmakon term debt, and announced a definitive agreement to acquire Astria Therapeutics, expected to close in the first quarter of 2026. These strategic moves are expected to enhance BioCryst’s market position and financial stability, with the company raising its full-year revenue guidance and lowering its operating expense outlook for 2025.

The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.